Synergy Pharmaceuticals Inc (SGYP):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9812)
◆英語タイトル:Synergy Pharmaceuticals Inc (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9812
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:50
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Synergy Pharmaceuticals Inc (Synergy Pharma) is a biopharmaceutical company that develops and commercializes new treatments for gastrointestinal (GI) diseases. The company pioneered its R&D efforts to develop its proprietary uroguanylin-based GI platform. It is also developing analogs of uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. The company’s portfolio includes Trulance (plecanatide), which is structurally identical to uroguanylin, for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. Synergy Pharma’s pipeline includes dolcanatide (SP-333), an investigational candidate under evaluation for the treatment of OIC and UC. Synergy Pharma is headquartered in New York, the US.

Synergy Pharmaceuticals Inc (SGYP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 12
Partnerships 13
Bind Therapeutics and Synergy Pharma Enter into Research Agreement 13
Licensing Agreements 14
Shandong Luoxin Pharma Enters into Licensing Agreement with Synergy Pharma 14
Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 15
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 16
Equity Offering 17
Synergy Pharma Prices Public Offering of Shares for USD56 Million 17
Synergy Pharma Raises USD125 Million in Public Offering of Shares 19
Synergy Pharma Plans to Raise Funds in Public Offering of Shares 20
Synergy Pharma Raises USD89.8 Million in Private Placement of Shares 21
Synergy Pharma Announces Public Offering Of Shares For Up To US$50 Million 22
ContraVir Pharma Spin Off from Synergy Pharma 23
Synergy Pharma Completes Public Offering Of Shares For US$90 Million 24
Synergy Pharma Completes Exercise Of Underwriters’ Option For Public Offering Of Shares For US$51.75 Million 26
Debt Offering 28
Synergy Pharma Raises USD79.8 Million in Private Placement of Notes Due 2019 28
Synergy Pharma Raises USD200 Million in Private Placement of 7.5% Notes Due 2019 29
Acquisition 31
Synergy Pharma Completes Acquisition Of Callisto Pharma 31
Synergy Pharmaceuticals Inc – Key Competitors 32
Synergy Pharmaceuticals Inc – Key Employees 33
Synergy Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Aug 07, 2018: Synergy Pharmaceuticals reports second quarter 2018 financial results and business update 35
May 10, 2018: Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update 37
Mar 01, 2018: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update 39
Nov 09, 2017: Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results 40
Aug 09, 2017: Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update 41
May 10, 2017: Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update 43
Mar 01, 2017: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update 45
Corporate Communications 47
Oct 31, 2018: Synergy Pharmaceuticals names Dr. Melvin K. Spigelman Chairman 47
Apr 17, 2017: Synergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer 48
Other Significant Developments 49
Oct 17, 2017: Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C) 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synergy Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 12
Bind Therapeutics and Synergy Pharma Enter into Research Agreement 13
Shandong Luoxin Pharma Enters into Licensing Agreement with Synergy Pharma 14
Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 15
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 16
Synergy Pharma Prices Public Offering of Shares for USD56 Million 17
Synergy Pharma Raises USD125 Million in Public Offering of Shares 19
Synergy Pharma Plans to Raise Funds in Public Offering of Shares 20
Synergy Pharma Raises USD89.8 Million in Private Placement of Shares 21
Synergy Pharma Announces Public Offering Of Shares For Up To US$50 Million 22
ContraVir Pharma Spin Off from Synergy Pharma 23
Synergy Pharma Completes Public Offering Of Shares For US$90 Million 24
Synergy Pharma Completes Exercise Of Underwriters' Option For Public Offering Of Shares For US$51.75 Million 26
Synergy Pharma Raises USD79.8 Million in Private Placement of Notes Due 2019 28
Synergy Pharma Raises USD200 Million in Private Placement of 7.5% Notes Due 2019 29
Synergy Pharma Completes Acquisition Of Callisto Pharma 31
Synergy Pharmaceuticals Inc, Key Competitors 32
Synergy Pharmaceuticals Inc, Key Employees 33
Synergy Pharmaceuticals Inc, Subsidiaries 34

List of Figures
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Synergy Pharmaceuticals Inc (SGYP):製薬・医療:M&Aディール及び事業提携情報(Synergy Pharmaceuticals Inc (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆